pirtobrutinib   Click here for help

GtoPdb Ligand ID: 11628

Synonyms: BTK inhibitor 16 | Jaypirca® | LOXO-305 | LOXO305 | MCL-133 | MCL133 | RXC005
Approved drug PDB Ligand Immunopharmacology Ligand
pirtobrutinib is an approved drug (FDA & EMA (2023))
Compound class: Synthetic organic
Comment: Pirtobrutinib (LOXO-305, MCL-133) is a selective and reversible (non-covalent), oral Bruton's tyrosine kinase (BTK) inhibitor that was originally developed by LOXO oncology (now Lilly Oncology) for potential to treat B cell malignancies [3,5]. It binds within the BTK kinase pocket but its interaction does not rely on the C481 residue that is essential for the activity of earlier irreversible BTK inhibitors (ibrutinib, acalabrutinib, and zanubrutinib). Therefore, it is expected to be active in cancers with wild type BTK or with C481 resistance mutations.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 3
Rotatable bonds 9
Topological polar surface area 125.26
Molecular weight 479.16
XLogP 4.44
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES COc1ccc(cc1C(=O)NCc1ccc(cc1)c1nn(c(c1C(=O)N)N)[C@H](C(F)(F)F)C)F
Isomeric SMILES COc1ccc(cc1C(=O)NCc1ccc(cc1)c1nn(c(c1C(=O)N)N)[C@H](C(F)(F)F)C)F
InChI InChI=1S/C22H21F4N5O3/c1-11(22(24,25)26)31-19(27)17(20(28)32)18(30-31)13-5-3-12(4-6-13)10-29-21(33)15-9-14(23)7-8-16(15)34-2/h3-9,11H,10,27H2,1-2H3,(H2,28,32)(H,29,33)/t11-/m0/s1
InChI Key FWZAWAUZXYCBKZ-NSHDSACASA-N
Download 2D Structure Click here for help
Canonical SMILES Download
Isomeric SMILES Download
InChI standard identifier Download
InChI standard key Download

Molecular structure representations generated using Open Babel